Xvivo Perfusion (Q1 Review): A strong start to an eventful year - Redeye

The report supported our take on increasing thoracic sales and showed continued FCF improvements (Q4 was the first quarter of positive cash flow). Still, the lower-than-expected gross margins held back a beat on profitability.

Länk till analysen i sin helhet: https://www.redeye.se/research/1161774/xvivo-perfusion-q1-review-a-strong-start-to-an-eventful-year?utm_source=finwire&utm_medium=RSS